D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
AVXL holding history
Anavex Life Sciences Corp. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
AVXL overviewAll 13F holders of AVXLFull Q2 2026 holdings
- Shares (Q2 2026)
- 115,462
- Value
- $299.0K
- % of portfolio
- <0.1%
- Quarters held
- 16
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 115,462 | $299.0K | <0.1% | +70,606+157.4% | Added | Holders |
| Q1 2026 | 44,856 | $137.7K | <0.1% | +44,856 | New | Holders |
| Q1 2025 | 0 | $0 | 0.0% | −105,130−100.0% | Sold out | Holders |
| Q4 2024 | 105,130 | $1.13M | <0.1% | +105,130 | New | Holders |
| Q3 2024 | 0 | $0 | 0.0% | −58,355−100.0% | Sold out | Holders |
| Q2 2024 | 58,355 | $246.3K | <0.1% | −11,263−16.2% | Reduced | Holders |
| Q1 2024 | 69,618 | $354.4K | <0.1% | +16,164+30.2% | Added | Holders |
| Q4 2023 | 53,454 | $497.7K | <0.1% | +20,913+64.3% | Added | Holders |
| Q3 2023 | 32,541 | $213.1K | <0.1% | −12,563−27.9% | Reduced | Holders |
| Q2 2023 | 45,104 | $366.7K | <0.1% | +45,104 | New | Holders |
| Q1 2023 | 0 | $0 | 0.0% | −46,190−100.0% | Sold out | Holders |
| Q4 2022 | 46,190 | $427.7K | <0.1% | −257,959−84.8% | Reduced | Holders |
| Q3 2022 | 304,149 | $3.14M | <0.1% | −73,205−19.4% | Reduced | Holders |
| Q2 2022 | 377,354 | $3.78M | <0.1% | +67,962+22.0% | Added | Holders |
| Q1 2022 | 309,392 | $3.81M | <0.1% | +292,864+1,771.9% | Added | Holders |
| Q4 2021 | 16,528 | $287.0K | <0.1% | −28,351−63.2% | Reduced | Holders |
| Q3 2021 | 44,879 | $806.0K | <0.1% | −54,814−55.0% | Reduced | Holders |
| Q2 2021 | 99,693 | $2.28M | <0.1% | +48,244+93.8% | Added | Holders |
| Q1 2021 | 51,449 | $769.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.